Intravitreal pegaptanib sodium (Macugen®) for diabetic macular oedema

. Purpose: To report the functional and anatomical outcomes resulting from the use of intravitreal pegaptanib sodium (Macugen®) in patients with diabetic macular oedema (DMO). Methods: We conducted a retrospective outcome analysis, by optical coherence tomography (OCT) and best‐corrected visual acuity (BCVA), of eyes with DMO treated with intravitreal pegaptanib sodium. Moreover, we evaluated the foveal transverse photoreceptor (PR) band integrity in the OCT images at the time of the last follow‐up visit. Results: Sixty‐three eyes of 48 patients with a minimum of 6 months of follow‐up were included for analysis. Intravitreal pegaptanib was found to produce significant improvements in mean BCVA (p = 0.019) and reductions in mean central macular thickness (CMT) (p